Total Funding
70
65
Total FundingPost-IPO Equity raised
Growth Score
-4 pts
Heat Score
-10 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
36056
Janux Therapeutics develops immunotherapies that generates immune responses to prevent tumors and not affecting a patient’s healthy tissue.
- David Campbell: Founder, President ,and Chief Executive OfficerPast Role: Sitari Pharmaceuticals, Chief Scientific Officer
- William Go: Chief Medical OfficerPast Role: BioMarin Pharmaceutical, Chief Development Officer
About the Company
Janux Therapeutics develops immunotherapies that generate immune responses to prevent tumors and not affecting a patient’s healthy tissue. Janux technology targets all three stages of the anti-tumor immune response.
